Fig. 1: EAPB02303 alone affects pancreatic cancer cell viability in vitro and reduces tumor growth in vivo. | Cell Death & Disease

Fig. 1: EAPB02303 alone affects pancreatic cancer cell viability in vitro and reduces tumor growth in vivo.

From: Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances paclitaxel effect in pancreatic cancer models

Fig. 1: EAPB02303 alone affects pancreatic cancer cell viability in vitro and reduces tumor growth in vivo.

EAPB02303 effect on cell viability was assessed using the SRB assay in the indicated PDAC cell lines (A), in 3D co-culture models with immortalized primary CAFs (ratio 1:50) (B), and in the indicated FOLFIRINOX-resistant (FR) and gemcitabine-resistant (GR) cell lines (C) (n = 3). Resistant cell line IC50 were compared to parental cell lines. Two tailed unpaired t-test p-values are reported ****p < 0.0001 ***p < 0.001, **p < 0.01, *p < 0.05. ns: not significant. Nude mice were xenografted with Pancpec (D) or P4604 (E) cells (n = 10 mice/group) and treated with EAPB02303 (3 mg/kg, 10 mg/kg, or 30 mg/kg) or vehicle (80% water, 0.9% NaCl, 10% DMSO, 10% Tween 20) 5 days/week for 30 days. Mouse weight and tumor size were measured throughout the experiment and Kaplan Meyer curves were computed. The significance is relative to the vehicle group. Error bars represents mean ± SEM. For tumor size and body weight, statistical testing using Linear Mixed-effect Models (LMMs) was performed, and p-values comparing the EAPB2303 30 mg/kg and vehicle groups are reported: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns: not significant.

Back to article page